Results 291 to 300 of about 1,461,609 (326)
Some of the next articles are maybe not open access.
Pharmacokinetics of Bispecific Antibody
Current Pharmacology Reports, 2017This article provides a brief overview of bispecific antibody (BsAb) mechanisms of action, structures, and pharmacokinetic (PK) properties, including absorption, distribution, and elimination. Recent trend in BsAb development is also introduced from a PK perspective.
Yang Chen, Yan Xu
openaire +2 more sources
Immunotherapeutic perspective for bispecific antibodies
Immunology Today, 2000Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
Annemiek B. van Spriel +2 more
openaire +3 more sources
Catumaxomab: A bispecific trifunctional antibody
Drugs of Today, 2009The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
Marcus Schmidt +3 more
openaire +3 more sources
Targeting cancer with bispecific antibodies [PDF]
Science, 2021 Bispecific antibodies might provide off-the-shelf immunotherapeutics for treating ...
openaire +2 more sources
Bispecific antibodies for delivery into the brain
Current Opinion in Chemical Biology, 2013The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J. Watts, Mark S. Dennis
openaire +3 more sources
Bispecific antibodies for the treatment of hemophilia A
Expert Opinion on Biological Therapy, 2021Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire +3 more sources
Bispecific Antibodies for Thrombolysis
1992The seach of new methods for treatment of “century deseases” such as cancer or atherosclerosis with associated thrombosis sets up a problem of targeting of biologically active substances to localized areas of organism. The use of bifunctional (chimeric) antibodies (particularly - bifunctional monoclonals - biMoAbs) as means of drug targeting becomes a ...
M. Yu. Matveyev +2 more
openaire +2 more sources
How to Make Bispecific Antibodies
2000This protocol describes the production of bispecific F(ab')2 antibody derivatives (BsAbs) by the linking of two Fab' fragments via their hinge region SH groups using the bifunctional crosslinker o-phenylenedimaleimide (o-PDM) as described by Glennie et al. (1,2). The procedure is illustrated in Fig. 1.
openaire +3 more sources
Bispecific antibodies in cancer therapy
Current Opinion in Immunology, 1999Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
George J. Weiner +2 more
openaire +2 more sources
T-cell-engaging bispecific antibodies in cancer
The Lancet, 2023N. Donk, S. Zweegman
semanticscholar +1 more source